Literature DB >> 33387895

Rapid and accurate eXDR screening: use Xpert Carba-R® with FecalSwab®.

Eric Farfour1, Alexandra Lomont2, Vincent Fihman3, Marion Lecuru4, Sophie Hüssler3, Souad Ouzani5, Jean-Ralph Zahar2, Laurent Dortet6.   

Abstract

The FecalSwab® displays high performances for stool culture, but it was not assessed for carbapenemase-producing Enterobacterales (CPE) screening. We assess the performances of the Xpert Carba-R v2® with the FecalSwab®. Using a collection of 12 CPE strains, the limit of detection was assessed at 158 CFU/swab [interquartile range 93-589]. In 2019, 1540 swabs were included by 4 hospital laboratories, of which 39 (2.5%) yield an invalid result. Among the 1501 valid, 87 (5.8%) were positives by culture and PCR and 25 (1.7%) were discrepant: 7 PCR-negative culture-positive, and 18 PCR-positive culture-negative. Two PCR-positive culture-negative results involved non-Enterobacterales strains: a KPC-producing Acinetobacter baumannii and a KPC-producing Aeromonas spp. The overall percent agreement was 98.3% and the Kappa value was 0.88. FecalSwab® is an accurate sampling device for CPE screening. It allows performing all eXDR screening using a single swab, simplifying the sample collection, and improving the patient comfort. Regarding discrepant, we suggest combining a CPE screening by both culture and Xpert Carba-R v2® methods.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Carbapenemase-producing Enterobacterales (CPE); EXDR; FecalSwab; Outbreak; Vancomycin-resistant Enterococcus (VRE); Xpert Carba; Xpert vanA/vanB

Year:  2020        PMID: 33387895     DOI: 10.1016/j.diagmicrobio.2020.115279

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  1 in total

1.  Comparison of the Clinical Outcomes of Patients With Positive Xpert Carba-R Tests for Carbapenemase-Producing Enterobacterales According to Culture Positivity.

Authors:  Hyeonji Seo; Jeong-Young Lee; Seung Hee Ryu; Sun Hee Kwak; Eun Ok Kim; Seongman Bae; Min Jae Kim; Yong Pil Chong; Sung-Han Kim; Sang-Oh Lee; Sang-Ho Choi; Heungsup Sung; Mi-Na Kim; Yang Soo Kim; Jiwon Jung
Journal:  Open Forum Infect Dis       Date:  2022-01-10       Impact factor: 3.835

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.